FY2025 · ended Dec 31, 2025 · Revenue $2.29M, +40.8% YoY · Filed Mar 31, 2026
Femasys Inc. (FEMY) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.3 million and a net loss of $18.6 million. Free cash flow was -$19.2 million. As of Jun 30, 2026 it held $1.4 million in cash and investments and $1.3 million in total debt.
Revenue (TTM)
$2.30M
+21.9% vs year-ago TTM
Net income (TTM)
$-11.77M
+44.0% vs year-ago TTM
Operating cash flow (TTM)
$-17.65M
+10.2% vs year-ago TTM
Free cash flow (TTM)
$-18.07M
+11.3% vs year-ago TTM
EPS (TTM)
$-0.29
+83.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
60.39M
+122.4% vs prior year
Net cash
$174,483
as of Jun 30, 2026
Operating margin
-763.9%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- FEMY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Suwanee, GA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1339005
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.3M | $1.6M | $1.1M | $1.2M | $1.2M |
| Operating income | -$17.6M | -$17.8M | -$14.5M | -$11.6M | -$8.3M |
| Net income | -$18.6M | -$18.8M | -$14.2M | -$11.4M | -$7.5M |
| Diluted EPS | -$0.47 | -$0.85 | -$0.93 | -$0.96 | -$1.12 |
| Operating cash flow | -$18.7M | -$19.4M | -$11.3M | -$10.7M | -$7.9M |
| Free cash flow | -$19.2M | -$20.2M | -$11.4M | -$11.1M | -$8.2M |
| Total assets | $20.7M | $12.4M | $27.8M | $16.9M | $28.6M |
| Total liabilities | $14.9M | $10.1M | $9.4M | $1.7M | $2.2M |
| Stockholders' equity | $5.9M | $2.3M | $18.4M | $15.2M | $26.3M |
| Cash and investments | $9.3M | $3.5M | $21.7M | $13.0M | $24.8M |
| Total debt | $1.5M | $2.0M | $2.4M | $402,417 | $809,091 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 2, 2026 | Oct 30, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 11, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Other events
|
Jun 24, 2026 | Jun 23, 2026 |
All 341 Femasys Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.